A randomized, double-blind study comparing single-dose rifalazil with single-dose azithromycin for the empirical treatment of nongonococcal urethritis in men

Autor: Nancy M. Kivel, Walter E. Stamm, William M. McCormack, Andrew Sternlicht, Byron E. Batteiger, Patricia A. Totten
Rok vydání: 2007
Předmět:
Microbiology (medical)
Adult
Male
Sexually Transmitted Diseases
Bacterial
medicine.medical_specialty
Non-gonococcal urethritis
Chlamydia trachomatis
Mycoplasma genitalium
Dermatology
Azithromycin
urologic and male genital diseases
medicine.disease_cause
Drug Administration Schedule
Ureaplasma
chemistry.chemical_compound
Double-Blind Method
Internal medicine
medicine
Humans
Urethritis
Mycoplasma Infections
biology
business.industry
Rifalazil
Ureaplasma Infections
Public Health
Environmental and Occupational Health
Rifamycin
Chlamydia Infections
bacterial infections and mycoses
biology.organism_classification
medicine.disease
Rifamycins
female genital diseases and pregnancy complications
Anti-Bacterial Agents
Infectious Diseases
Treatment Outcome
chemistry
Immunology
business
Ureaplasma urealyticum
Zdroj: Sexually transmitted diseases. 34(8)
ISSN: 0148-5717
Popis: Objectives To determine the safety and effectiveness of single-dose rifalazil, a new rifamycin, for the treatment of nongonococcal urethritis (NGU). Study design Randomized, double-blind trial comparing rifalazil, 2.5, 12.5 or 25 mg, with 1.0 g azithromycin for the treatment of NGU. One hundred and seventy men were evaluated for Chlamydia trachomatis, Ureaplasma urealyticum, and Mycoplasma genitalium infection before therapy and 2- and 5-weeks posttreatment. Results C. trachomatis, M. genitalium, and U. urealyticum were present in 42%, 24%, and 28% of subjects, respectively. Microbiologic eradication of C. trachomatis with rifalazil 25 mg at 2- and 5- weeks was 85% and 83%, respectively. Rifalazil was ineffective in eradicating M. genitalium and U. urealyticum. Overall clinical cure rates at 2- and 5-weeks were 86% (95% CI 67-96) and 59% (39-78) in the rifalazil-treated 25 mg group, and 77% (56-91) and 63% (41-81) in the azithromycin-treated group. Conclusions Rifalazil was well tolerated and eradicates C. trachomatis but not M. genitalium and U. ureaplasma in men with NGU.
Databáze: OpenAIRE
Externí odkaz: